Clinuvel Pharmaceuticals Limited
ASX: CUV.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Philippe Jacques Wolgen
- Employees
- 16
- Headquarters
- Melbourne, Australia
- IPO year
- 2001
- Market cap
- A$477.4M
- Website
- https://www.clinuvel.com
Loading CUV…
Loading profile data…Frequently asked questions about CUV
What does Clinuvel Pharmaceuticals Limited (CUV.AX) do?
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention...
Where does CUV.AX trade?
Clinuvel Pharmaceuticals Limited (CUV.AX) trades on the Australian Securities Exchange.
What sector is CUV.AX in?
Clinuvel Pharmaceuticals Limited (CUV.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Clinuvel Pharmaceuticals Limited?
Philippe Jacques Wolgen is the chief executive officer of Clinuvel Pharmaceuticals Limited (CUV.AX).
Where is Clinuvel Pharmaceuticals Limited headquartered?
Clinuvel Pharmaceuticals Limited is headquartered in Australia.
Does CUV.AX pay a dividend?
Yes — Clinuvel Pharmaceuticals Limited (CUV.AX) paid a trailing twelve-month dividend of AUD 0.05 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did CUV.AX go public?
Clinuvel Pharmaceuticals Limited (CUV.AX) completed its initial public offering in 2001.